![]() Poster NR6-34: Efficacy of Long-Acting Risperidone in Patients with Schizophrenia : A Six-Month Follow Up from the E-Star Database in Latin America Poster NR6-12: A Randomized Double-Blind, Comparative Study of Paliperidone Palmitate and Risperidone Long-Acting Therapy in Patients with Schizophrenia Poster NR6-7: Long-Term Safety, Tolerability And Pharmacokinetics of Paliperidone Palmitate: A One-Year, Open-Label Study in Patients with Schizophrenia Poster NR6-5: Onset of Efficacy with Paliperidone Palmitate in Patients with Acutely Exacerbated Schizophrenia Poster NR6-21: Tolerability of Paliperidone Palmitate Initiation Doses in Subjects with Recently Diagnosed Schizophrenia Poster NR6-26: Effects of Paliperidone Palmitate in Acutely Ill Subjects with a Marked-to-Severe Exacerbation of Schizophrenia Poster NR6-17: Effects of Paliperidone Palmitate Treatment in Schizophrenia Patients Previously Treated with Oral Risperidone ![]() or Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Ortho-McNeil Janssen Scientific Affairs, L.L.C. The posters address topics such as efficacy in different populations of patients with schizophrenia long-term pharmacokinetics and long-term safety and pharmacoeconomics. ![]() Posters on this data will be presented on Wednesday, May 26, from 12 noon to 2 pm at the meeting. Titusville, NJ, New data on INVEGA® SUSTENNA® (paliperidone palmitate), a long-acting injectable medicine for schizophrenia, and new data on RISPERDAL® CONSTA® (risperidone long-acting therapy), also an injectable medicine to treat schizophrenia, will be presented this week at a major psychiatry meeting in New Orleans. ![]() New Data on Invega ® Sustenna ® and Risperdal ® Consta ® For Schizophrenia ![]()
0 Comments
Leave a Reply. |